Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Equity Premium Income ETF (JEPI) vs Novartis AG (NVS) Price & Performance

JPMorgan Equity Premium Income ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

JPMorgan Equity Premium Income ETF vs Novartis AG — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.82, while Novartis AG trades at $152.7 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while JPMorgan Equity Premium Income ETF pays none, and Novartis AG is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

JEPINVS
Sector
Income / Options OverlayHealth
52-Week High
$59.88$168.62
52-Week Low
$55.29$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Equity Premium Income ETF

JEPI trades at $57.8, up 0.28% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating income through covered calls, offering monthly dividends, but key valuation ratios are not publicly disclosed. Recent news highlights its popularity among retirees for yield, though some articles note underperformance versus peers.

Outlook is mixed: strong income appeal supports demand, but competition and potential tax inefficiencies pose risks. Investors should weigh the high yield against total return lag and market volatility exposure. The bullish technical trend may face resistance near current levels if overbought conditions persist.

Novartis AG

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.

Read more on JEPI

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS